Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 8

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 8
---
. In addition, we have conducted a pre-clinical animal model of AUD to
characterize the effect of MEAI on alcohol consumption. This study involved testing the effect of MEAI’s ability to curb alcohol
cravings after exposing mice to prolonged alcohol consumption over a short period, mimicking binge alcohol consumption in humans.

In February 2024 and in July
2024, we announced that we were granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate our first-in-human
Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD. Subsequently, we initiated the CM-CMND-001 clinical trial in
both Israel and the United States, including at the Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University
School of Medicine. In October 2024 and December 2024, we announced that we received IRB approvals from Johns Hopkins University and Yale
University, respectively, our clinical sites, for part A of our Phase I/IIa clinical trial in the United States for treating patients
suffering from AUD. After Phase I/IIa study initiation in Israel in March 2025, we initiated our Phase I/IIa clinical trial at the Johns
Hopkins University School of Medicine and Yale School of Medicine’s Department of Psychiatry in April 2025. In June 2025, we announced
the addition of Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel and Hadassah-University Medical Center in Jerusalem, Israel
as additional clinical sites for our ongoing Phase I/IIa clinical trial. In addition, also in June 2025, we announced that the first patient
was enrolled and dosed in our Phase I/IIa clinical trial at Yale School of Medicine’s Department of Psychiatry. In July 2025, we
announced that we received IRB approval from TASMC for our Phase I/IIa clinical trial , and in August 2025, we announced that we received
IRB approval from Hadassah-University Medical Center. In July 2025, we announced initiation of the TASMC clinical site.

<div align='center'>1</div>

The CM-CMND-001 clinical trial
is designed to be a multinational, multi-center, double blind, Phase I/IIa single- and multiple-dose tolerability, safety and pharmacokinetic
study in healthy volunteers and AUD subjects. Upon completion of the Phase I/II